These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29777424)

  • 21. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use and misuse of triptans in France: data from the GRIM2000 population survey.
    Lucas C; Auray JP; Gaudin AF; Dartigues JF; Duru G; Henry P; Lantéri-Minet M; Pradalier A; Chazot G; El Hasnaoui A
    Cephalalgia; 2004 Mar; 24(3):197-205. PubMed ID: 15009013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute treatment patterns in patients with migraine newly initiating a triptan.
    Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey.
    Nedergaard L; Martens MC; Christensen MDB; Pellesi L
    Pain Pract; 2024 Jul; 24(6):832-838. PubMed ID: 38450841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Lee JH; Shewale AR; Barthold D; Devine B
    Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptans: low utilization and high turnover in the general population.
    Panconesi A; Pavone E; Franchini M; Mennuti N; Bartolozzi M; Guidi L; Banfi R
    Cephalalgia; 2010 May; 30(5):576-81. PubMed ID: 19732070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.
    Deighton AM; Harris LA; Johnston K; Hogan S; Quaranta LA; L'Italien G; Coric V
    BMC Neurol; 2021 Nov; 21(1):425. PubMed ID: 34727873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptan use in Australia 1997-2015: A pharmacoepidemiological study.
    Eyre BLKD; Eadie MJ; van Driel ML; Ross-Lee L; Hollingworth SA
    Acta Neurol Scand; 2017 Aug; 136(2):155-159. PubMed ID: 28093722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ergot and triptan overuse in Austria--an evaluation of clinical data and cost.
    Lampl C; Buzath A; Yazdi K; Sandor PS
    Cephalalgia; 2002 Dec; 22(10):807-11. PubMed ID: 12485206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment adherence among new triptan users: a 2-year cohort study in Taiwan.
    Chen TB; Chen YT; Fuh JL; Tang CH; Wang SJ
    J Headache Pain; 2014 Aug; 15(1):48. PubMed ID: 25117594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
    Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of migraine medication use in Norway: A nationwide registry-based observational study.
    Stubberud A; Borkenhagen S; Oteiza F; Dueland AN; Bugge C; Sæther EM; Tronvik E; Stovner LJ; Bjørk MH
    Cephalalgia; 2024 Aug; 44(8):3331024241268212. PubMed ID: 39149980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Martínez-Pías E; García-Azorín D; Minguez-Olaondo A; Trigo J; Sierra Á; Ruiz M; Guerrero ÁL
    Expert Rev Neurother; 2021 Jan; 21(1):123-130. PubMed ID: 33111580
    [No Abstract]   [Full Text] [Related]  

  • 38. Patterns of use and health expenses associated with triptans among adults with migraines.
    Wu J; Noxon V; Lu ZK
    Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
    Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
    Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.